GlassScriptPhysician profile
Matthew Orwitz
NPI 1518462480
$875.94
in general payments reported to CMS, 2019-2025
19 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $33.24 · 2024: $184 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $121.91 | 2025 | Gore Cardioform Septal Occluder |
| Sk Life Science, INC. | $107.07 | 2024-2025 | |
| Abbvie INC. | $103.94 | 2023-2025 | |
| Impel Pharmaceuticals LLC | $73.43 | 2025 | Trudhesa |
| Ucb, INC. | $72.48 | 2024-2025 | Briviact, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $59.54 | 2024-2025 | Austedo Xr, Ajovy |
| Boston Scientific Corporation | $49.85 | 2024-2025 | General - Dbs |
| Lundbeck LLC | $49.33 | 2024-2025 | Vyepti |
| Eisai INC. | $36.90 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $31.04 | 2025 | Crexont |
| Ceribell, INC. | $26.07 | 2025 | Pocket Eeg Device |
| Vanda Pharmaceuticals INC. | $18.97 | 2024 | Ponvory |
| Astrazeneca Pharmaceuticals LP | $18.66 | 2024 | Wainua |
| Pfizer INC. | $18.60 | 2025 | |
| Neurelis, INC. | $18.59 | 2025 | Valtoco |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $17.91 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Axsome Therapeutics, INC. | $17.30 | 2025 | Symbravo |
| Biogen, INC. | $17.25 | 2024 | Leqembi |
| Alexion Pharmaceuticals, INC. | $17.10 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Orwitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.